Gilead pays USD45M to secure Kymera’s unique CDK2 molecular glue for cancer

USA—Gilead Sciences has strengthened its oncology pipeline by exercising a USD 45 million option on Kymera Therapeutics’ preclinical anticancer compound.

This decision marks a significant expansion of the two companies’ partnership, which began with Gilead’s USD40 million investment for an exclusive option in June 2025.

The deal was triggered when Kymera completed discovery and preclinical research, ultimately delivering a comprehensive data package that convinced Gilead to move forward.

The arrangement demonstrates the successful collaboration between both organizations, as they jointly identified and refined a promising development candidate for further advancement.

Gilead’s latest payment more than doubles Kymera’s financial returns from the partnership and establishes a pathway for the biotech to earn up to $665 million in additional development, regulatory, and commercial milestones.

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

Shifting away from traditional approaches

Rather than employing conventional small-molecule inhibitors that bind to CDK2, Kymera engineered a molecular glue degrader that physically removes the kinase protein.

This innovative approach differentiates KT-200 from competitors already in clinical trials, as Kymera claims the compound demonstrates superior selectivity for CDK2 compared to traditional small-molecule alternatives.

By maintaining higher specificity, the drug candidate may avoid dose-limiting toxicities caused by unintended CDK1 inhibition, offering patients a safer and more effective treatment option.

Preclinical testing has already demonstrated KT-200’s effectiveness, achieving low-nanomolar degradation of CDK2.

Building on these promising results, Gilead plans to conduct IND-enabling studies to initiate human trials next year.

Growing clinical interest in CDK2

Interest in CDK2 targeting has accelerated recently, driven by limitations in existing cancer therapies.

Although CDK4/6 inhibitors have improved outcomes for certain breast cancer patients, disease progression remains inevitable, and expansion efforts into additional tumor types have encountered obstacles.

Consequently, researchers have intensified their focus on alternative strategies, with CDK2 emerging as an increasingly attractive target.

Several major pharmaceutical companies have already advanced their own CDK2 programs.

Pfizer is approaching completion of phase 1/2 data for its candidate in both monotherapy and combination settings, while Incyte launched a phase 1 trial in 2022.

AstraZeneca entered clinical development the following year, and Blueprint Medicines retains preclinical CDK2 prospects despite discontinuing a previous candidate.

These parallel efforts underscore the therapeutic potential of CDK2 inhibition across multiple cancer indications.

Strategic pipeline growth

Gilead’s decision reflects the company’s aggressive expansion following three major acquisitions exceeding USD12 billion total.

Although executives have indicated plans to pause large-scale buyouts and focus on integration, the pharmaceutical company continues to pursue smaller, strategic partnerships.

On the same day Kymera announced its arrangement, Gilead exercised an additional oncology option with Cartography Biosciences while expanding its collaboration with Tempus AI in oncology research.